Emily Bodnar’s rating relies on the anticipation of sizeable milestones for Agenus in the coming 12 months, especially the likely filing of a Biologics License Application (BLA) for his or her lead drug candidate, botensilimab (bot). Agenus has dosed around 900 individuals with bot across several solid tumors, showing a commitment to substantial